Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yuantian Biopharma is a clinical-stage biotechnology company based in Beijing, China, specializing in the discovery and development of innovative biologics for oncology and autoimmune diseases. Founded by Dr. Yuan Tian, a veteran of global pharmaceutical R&D, the company leverages proprietary platforms to engineer next-generation antibodies and fusion proteins. Its lead program, YT-101, is a bifunctional fusion protein targeting the PD-L1 and TGF-beta pathways, currently in Phase 1 clinical trials for advanced solid tumors. The company's pipeline also includes bispecific antibodies targeting CD47 and other immune checkpoints designed to overcome resistance to existing immunotherapies. Yuantian Biopharma is backed by prominent investors such as Legend Capital and Northern Light Venture Capital.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Yuan Tian.